Theme watch · accelerating
medtech stocks to watch · August 2026
As of 2026-08-09
MolDX overhang lifted 2026-07-16, then the 2026-07-30 print converted policy into numbers: FY2026 revenue guide raised to $490–500M from…
Sell-side discovery leg is spent: three Strong Buys with a $30.67 average against $28.68 (2026-07-17) leaves ~7% to consensus. The July 13 warrant…
Post-collapse deleveraging read: Q3 FY26 (2026-08-07) beat at $271.7M revenue and $0.56 adj EPS vs $0.27, and the FY26 adj EPS guide went to…
Since MIMEDX's 2026-07-29 definitive agreement ($33.00 cash + 0.4735 MDXG shares, ~$35 headline, ~$350M EV), SMTI trades as a merger-arb…
Beaten-down insulin-pump turnaround; the whole re-rate hinges on the tubeless Mobi ("Toby") 510(k) — planned for a Q2 filing but still unconfirmed…
"3-mo price move" is the stock's market price change, not an orbyd return.
How this page is built
These are the names orbyd covers in the medtech stocks cluster — each with a dated research dossier. Names currently on the move rank first by 3-month price momentum, then the rest of the covered roster. Cluster membership is assigned by a frontier model, currently read as accelerating.
New cluster carried by 3-month momentum (CDNA 115.7, PLSE 108.1, SMTI 78.6) plus this week's prints: Embecta beat at $0.56 vs $0.27 and raised FY26 adjusted EPS guidance to $1.80-$1.90 (08-07), and BTIG lifted CareDx to a $60 target (08-06). The weaker members argue caution Tandem's sales missed at $254.56M (08-06) and Pulse Biosciences booked $434K against a $533K estimate (08-06) so the theme is device-earnings-driven, not a single narrative.
Questions
- What medtech stocks does orbyd cover?
- As of 2026-08-09, the medtech stocks orbyd tracks are led by CDNA, PLSE, EMBC, SMTI, each with a dated research dossier. Names already moving rank first by 3-month price momentum; this is research, not a recommendation.
- Is the medtech stocks theme accelerating or slowing?
- orbyd's model reads this cluster as accelerating as of 2026-08-09. New cluster carried by 3-month momentum (CDNA 115.7, PLSE 108.1, SMTI 78.6) plus this week's prints: Embecta beat at $0.56 vs $0.27 and raised FY26 adjusted EPS guidance to $1.80-$1.90 (08-07), and BTIG lifted CareDx to a $60 target (08-06). The weaker members argue caution Tandem's sales missed at $254.56M (08-06) and Pulse Biosciences booked $434K against a $533K estimate (08-06) so the theme is device-earnings-driven, not a single narrative.
- How does orbyd rank medtech stocks?
- Every name links to its dated research dossier. Those currently on the move rank first by cross-sectional 3-month price momentum, then the rest of the covered roster by conviction. Methodology is open; this is research, not advice.
Related
As of 2026-08-09 · research, not advice.